Skip to main content
Erschienen in: Archives of Dermatological Research 4/2021

08.07.2020 | Original Paper

Association of inflammatory skin diseases with venous thromboembolism in US adults

verfasst von: Mohammed S. Shaheen, Jonathan I. Silverberg

Erschienen in: Archives of Dermatological Research | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Patients with certain inflammatory skin diseases have multiple risk factors for venous thromboembolism (VTE). The objective of the study was to determine whether atopic dermatitis (AD), psoriasis, pemphigus, pemphigoid and/or hidradenitis is associated with VTE in US adults. Data were analyzed from the 2002–2012 Nationwide Inpatient Sample, a representative cohort of US hospitalizations (N = 72,512,581 adults, including 1,389,292 with VTE). In multivariable logistic regression models including age, sex, insurance, household income and race/ethnicity, hospitalization for AD (adjusted odds ratio [95% confidence intervals] 1.22 [1.17–1.27]), pemphigus (1.96 [1.68–2.28]) and pemphigoid (1.64 [1.47–1.83]) was associated with VTE. These associations remained significant in virtually all patient subsets, including males and females, different age groups and those with and without long-term corticosteroid use. In particular, AD, pemphigus and pemphigoid were each associated with DVT and PE. VTE was associated with increased inpatient length of stay, cost of care and mortality across all the inflammatory skin diseases. HS and psoriasis were not consistently associated with VTE. AD, pemphigus and pemphigoid and some subsets of patients with HS were associated with higher odds of hospitalization for VTE. Patients with these inflammatory skin diseases may benefit from increased screening and prevention of VTE.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat ISTH Steering Committee for World Thrombosis Day (2014) Thrombosis: a major contributor to global disease burden. J Thromb Haemost 12(10):1580–1590 ISTH Steering Committee for World Thrombosis Day (2014) Thrombosis: a major contributor to global disease burden. J Thromb Haemost 12(10):1580–1590
3.
Zurück zum Zitat Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16PubMed Anderson FA Jr, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107(23 Suppl 1):I9–I16PubMed
4.
Zurück zum Zitat Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ (2011) Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 9:1CrossRef Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ (2011) Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 9:1CrossRef
5.
Zurück zum Zitat Chung WS, Lin CL, Sung FC, Lu CC, Kao CH (2014) Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res 134(3):622–626CrossRef Chung WS, Lin CL, Sung FC, Lu CC, Kao CH (2014) Increased risk of venous thromboembolism in patients with dermatomyositis/polymyositis: a nationwide cohort study. Thromb Res 134(3):622–626CrossRef
6.
Zurück zum Zitat Ahlehoff O, Gislason GH, Lindhardsen J et al (2011) Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE 6(3):e18125CrossRef Ahlehoff O, Gislason GH, Lindhardsen J et al (2011) Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS ONE 6(3):e18125CrossRef
7.
Zurück zum Zitat Johannesdottir SA, Horvath-Puho E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173(9):743–752CrossRef Johannesdottir SA, Horvath-Puho E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173(9):743–752CrossRef
8.
Zurück zum Zitat Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167(9):935–943CrossRef Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA (2007) Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 167(9):935–943CrossRef
10.
Zurück zum Zitat Leshem YA, Atzmony L, Dudkiewicz I, Hodak E, Mimouni D (2017) Venous thromboembolism in patients with pemphigus: a cohort study. J Am Acad Dermatol 77(2):256–260CrossRef Leshem YA, Atzmony L, Dudkiewicz I, Hodak E, Mimouni D (2017) Venous thromboembolism in patients with pemphigus: a cohort study. J Am Acad Dermatol 77(2):256–260CrossRef
11.
Zurück zum Zitat Nastalek M, Wojas-Pelc A, Undas A (2010) Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy. J Thromb Thrombolysis 30(2):121–126CrossRef Nastalek M, Wojas-Pelc A, Undas A (2010) Plasma fibrin clot properties in atopic dermatitis: links between thrombosis and atopy. J Thromb Thrombolysis 30(2):121–126CrossRef
12.
Zurück zum Zitat Miller IM, Ahlehoff O, Ibler K et al (2016) Hidradenitis suppurativa may not be associated with venous thromboembolia: results from a large Danish cross-sectional study. J Dermatol Sci 81(1):61–63CrossRef Miller IM, Ahlehoff O, Ibler K et al (2016) Hidradenitis suppurativa may not be associated with venous thromboembolia: results from a large Danish cross-sectional study. J Dermatol Sci 81(1):61–63CrossRef
13.
Zurück zum Zitat Waljee AK, Rogers MA, Lin P et al (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357:j1415CrossRef Waljee AK, Rogers MA, Lin P et al (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357:j1415CrossRef
14.
Zurück zum Zitat Zoller B, Li X, Sundquist J, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379(9812):244–249CrossRef Zoller B, Li X, Sundquist J, Sundquist K (2012) Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 379(9812):244–249CrossRef
15.
Zurück zum Zitat Davidovici BB, Sattar N, Prinz J et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130(7):1785–1796CrossRef Davidovici BB, Sattar N, Prinz J et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130(7):1785–1796CrossRef
16.
Zurück zum Zitat Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131(4):417–430CrossRef Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131(4):417–430CrossRef
17.
Zurück zum Zitat Kasperska-Zajac A, Brzoza Z, Rogala B (2008) Platelet function in cutaneous diseases. Platelets 19(5):317–321CrossRef Kasperska-Zajac A, Brzoza Z, Rogala B (2008) Platelet function in cutaneous diseases. Platelets 19(5):317–321CrossRef
18.
Zurück zum Zitat Chung WS, Peng CL, Lin CL et al (2014) Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 73(10):1774–1780CrossRef Chung WS, Peng CL, Lin CL et al (2014) Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 73(10):1774–1780CrossRef
19.
Zurück zum Zitat Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375(9715):657–663CrossRef Grainge MJ, West J, Card TR (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375(9715):657–663CrossRef
20.
Zurück zum Zitat Saleh T, Matta F, Yaekoub AY, Danescu S, Stein PD (2011) Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost 17(3):254–258CrossRef Saleh T, Matta F, Yaekoub AY, Danescu S, Stein PD (2011) Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost 17(3):254–258CrossRef
Metadaten
Titel
Association of inflammatory skin diseases with venous thromboembolism in US adults
verfasst von
Mohammed S. Shaheen
Jonathan I. Silverberg
Publikationsdatum
08.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 4/2021
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-020-02099-6

Weitere Artikel der Ausgabe 4/2021

Archives of Dermatological Research 4/2021 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.